Conference paper
SHORT-TERM KETAMINE ADMINISTRATION IN TREATMENT-RESISTANT DEPRESSION PATIENTS: FOCUS ON ADVERSE EFFECTS ON THE CENTRAL NERVOUS SYSTEM
Adam Włodarczyk
; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland
Wiesław Jerzy Cubała
; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland
Joanna Szarmach
; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland
Antonina Małyszko
; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland
Mariusz S. Wiglusz
; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdańsk, Poland
Abstract
Major depressive disorder (MDD) is a recurrent, incapacitating psychiatric illness which will be the second most disabling
disease worldwide by the year 2020. There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine,
which may be used in the treatment of resistant depression. Many of the studies are in favor of the drug, even in single dose
application, with effects appearing in minutes to hours from administration. However, there is a need to evaluate the benefits and
risks regarding psychomimetic, psychiatric, neurologic, and cognitive adverse effects of ketamine administration. The most
distressing symptoms which appear most frequently during ketamine administration are dissociative symptoms, which can be
quantified as a CNS adverse drug reaction. Results generally show that a single infusion of ketamine is efficacious and welltolerated,
while dissociative symptoms tend to abate within 2 hours after ketamine administration. As studies show single doses of
ketamine should be definitely considered as an option in TRD patients with/without suicidal thoughts, even though it could not
provide remission, or the effect could be temporary, but improving patients’ quality of life by reducing depressive symptomatology
should be a major asset while considering this particular procedure, particularly in inpatients.
Keywords
ketamine; MDD; treatment resistant depression; central nervous system; safety
Hrčak ID:
264166
URI
Publication date:
4.9.2019.
Visits: 318 *